Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Formoterol Fumarate; Salmeterol Xinafoate; Terbutaline

Criteria

Inclusion Criteria:

• Diagnosed with asthma since at least 6 months prior to first visit

• Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit

• At least one asthma exacerbation more than one but less than twelve months prior to first visit

Exclusion Criteria:

• Respiratory infection affecting asthma within 30 days before first visit

• Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit

• Any significant disease or disorder that may jeopardize the safety of the patient

Additional inclusion and exclusion criteria will be evaluated by the Investigator.